Cerebral Microembolism in Cardiology

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

During different interventional cardiology procedures we aim to identify cerebral microemboli load. Further we aim to differentiate the quality and the quantity of cerebral microemboli.We will measure cerebral microemboli in different interventional phases, e.g. during valve deployment, rapid pacing, post-implantation.

See also
Status	Clinical Trial	Phase
Completed	`NCT02021045` - Cerebral Microembolism During Hemodialysis	N/A
Completed	`NCT02378116` - Left Atrial Appendage Closure During Open Heart Surgery	N/A
Completed	`NCT01028794` - Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients	Phase 1/Phase 2
Terminated	`NCT02621749` - Cerebral Microembolism in the Critically Ill With Acute Kidney Injury	N/A

NCT number	NCT03802760
Study type	Observational
Source	University Hospital Inselspital, Berne
Contact
Status	Completed
Phase
Start date	October 24, 2018
Completion date	November 6, 2022

Cerebral Microembolism in Cardiology — ZEMEK

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms